Tailored for you

In-depth Analysis Tailored to Specified Regions or Segments
Company Profiles Customized to User Preferences
Comprehensive Insights Focused on Specific Segments or Regions

+1 2315155523

Efavirenz Market Size & CAGR Forecast 2025–2033

Efavirenz Market

Efavirenz Market Size & CAGR Forecast 2025–2033

Efavirenz Market by Type (Single Efavirenz, Two-drug combination, Three-drug combination), by Application (Adults, Children), by End User (Hospitals, Clinics, Others), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast 2026-2034

Updated On : May 22, 2026|Base Year : 2025|Pages : 0

Key Insights into the Efavirenz Market

The global Efavirenz Market is valued at $141.69 million in 2025 and is projected to expand at a compound annual growth rate (CAGR) of 4.78% through 2033, reflecting sustained demand for one of the most widely prescribed non-nucleoside reverse transcriptase inhibitors (NNRTIs) in HIV management. This trajectory is anchored by the continued global burden of HIV/AIDS, particularly in low- and middle-income countries, where efavirenz-based regimens remain a cost-effective frontline therapeutic option.

Efavirenz Market Research Report - Market Overview and Key Insights — Efavirenz Market Market Size (In Million)

The market's forward momentum is primarily driven by the WHO-recommended integration of efavirenz into first-line antiretroviral therapy (ART) protocols, particularly in sub-Saharan Africa and South and Southeast Asia. Nationally funded HIV treatment programs supported by organizations such as PEPFAR, the Global Fund, and UNAIDS continue to procure efavirenz at scale, ensuring a stable demand baseline. The Antiretroviral Drugs Market, of which efavirenz is a critical component, supports this procurement-driven demand.

Efavirenz Market Market Size and Forecast (2024-2030) — Efavirenz Market Company Market Share

Simultaneously, the proliferation of generic formulations has dramatically reduced per-unit costs, enabling wider access while keeping overall market value growth moderate. The rise of fixed-dose combinations (FDCs) incorporating efavirenz — particularly the three-drug regimen combining efavirenz, tenofovir, and emtricitabine — has reinforced its clinical utility and prolonged product lifecycle beyond what standalone molecules typically achieve.

From a macro perspective, increasing diagnosis rates, expanded ART eligibility under the UNAIDS 95-95-95 targets, and improving healthcare infrastructure in emerging economies are all generating incremental demand. The HIV Treatment Market continues to evolve with newer integrase strand transfer inhibitors (INSTIs) gaining ground in high-income settings, but efavirenz retains strong positioning in resource-constrained healthcare systems due to its established safety profile, extensive clinical history, and lower cost.

Looking ahead through 2033, the Efavirenz Market is expected to benefit from ongoing pediatric formulation development, regulatory approvals for improved dispersible tablet formats, and supply agreements between generic manufacturers and global health procurement agencies. The market will also be shaped by competitive dynamics among Indian and Chinese API manufacturers, who collectively supply the bulk of raw efavirenz substance globally. Overall, the market presents a resilient, volume-driven growth profile with moderate revenue escalation, making it an important segment within the broader Non-Nucleoside Reverse Transcriptase Inhibitors Market.

Dominance of Three-Drug Combination Segment in the Efavirenz Market

The three-drug combination segment constitutes the largest revenue-generating category within the Efavirenz Market, accounting for a dominant share of total sales by both volume and value. This dominance is structurally embedded in global HIV treatment guidelines, clinical practice norms, and procurement policies endorsed by major health institutions worldwide.

Three-drug fixed-dose combinations (FDCs) containing efavirenz — most commonly paired with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) or emtricitabine (FTC) — are the backbone of first-line ART in many low- and middle-income countries. The WHO's consolidated HIV treatment guidelines recommend TDF + 3TC (or FTC) + efavirenz as a preferred regimen in multiple population categories, cementing the three-drug combination's clinical primacy. This standardization translates directly into large-scale procurement contracts that overwhelmingly favor FDC formats.

The key advantage of the three-drug combination format lies in its pill burden reduction, which directly improves patient adherence — a critical factor in HIV management where lifelong therapy is required. A single once-daily pill combining all three active ingredients has been shown in multiple clinical trials to yield adherence rates significantly superior to multi-pill regimens. This pharmacological convenience drives both prescriber preference and patient demand, reinforcing the segment's market leadership.

From a competitive standpoint, several manufacturers have positioned themselves as dominant suppliers of efavirenz-based three-drug combinations. Cipla was among the first generic manufacturers to develop and scale production of this combination, earning a central role in global health procurement networks. Aurobindo Pharma and Mylan (now part of Viatris) have similarly invested in WHO prequalification of their FDC products, enabling participation in PEPFAR and Global Fund tenders. Strides Pharma and Hetero maintain competitive positions in select geographies, particularly in African markets.

The Fixed-Dose Combination Drugs Market dynamics significantly influence this segment, as patent expiry on originator products has unlocked a highly competitive generic landscape where price is the primary differentiator. Cost-per-treatment-day for efavirenz-based FDCs has declined substantially over the past decade, with median prices in donor-funded markets falling to levels that make broad access feasible.

Despite competitive pressure from newer INSTI-based regimens in high-income markets, the three-drug efavirenz combination retains a structural advantage in resource-constrained healthcare settings due to its established efficacy record, cold-chain independence, and compatibility with existing healthcare infrastructure. Regulatory agencies including the USFDA (through its Tentative Approval pathway under PEPFAR) and the WHO Prequalification Programme continue to approve new generic entrants, maintaining competitive pricing pressure that sustains high-volume procurement.

The segment's share is expected to remain largely stable through 2033, with some gradual erosion anticipated in middle-income countries as national programs transition toward dolutegravir-based regimens. However, in the lowest-income markets where cost sensitivity is most acute, efavirenz three-drug combinations will likely maintain therapeutic relevance for the foreseeable forecast horizon. The overall trajectory suggests a consolidating rather than expanding share, with volume growth in high-burden geographies partially offsetting value share compression in transitioning markets.

Efavirenz Market Market Share by Region - Global Geographic Distribution — Efavirenz Market Regional Market Share

Key Market Drivers and Constraints in the Efavirenz Market

Several quantifiable forces shape the demand and supply trajectory of the Efavirenz Market. Understanding these dynamics requires a data-centric examination of both accelerators and headwinds.

Driver 1: Scale of HIV/AIDS Burden Approximately 39 million people were living with HIV globally as of 2023, according to UNAIDS. Of these, roughly 29.8 million were accessing ART. Efavirenz-based regimens remain a first-line option for a substantial portion of this treated population, particularly in sub-Saharan Africa, which accounts for over 65% of global HIV burden. This epidemiological scale provides a structurally durable demand base.

Driver 2: Global Health Procurement Architecture PEPFAR committed approximately $7 billion in HIV/AIDS assistance in fiscal year 2023, with a significant portion allocated to ART procurement. The Global Fund's HIV allocation for 2023–2025 exceeds $6 billion. These funding flows directly support efavirenz FDC procurement, providing revenue visibility for manufacturers over multi-year horizons.

Driver 3: Pediatric Formulation Demand The children segment remains underpenetrated relative to the adult segment, creating a growth opportunity. Fewer than 50% of HIV-positive children globally were accessing ART as of 2023, and dispersible efavirenz formulations approved for pediatric use are expected to address this gap as healthcare outreach expands.

Constraint 1: Dolutegravir Displacement Dolutegravir (DTG), an integrase inhibitor, has been widely endorsed as a preferred first-line agent due to its superior resistance barrier and tolerability profile. Since 2019, WHO has recommended DTG-based regimens as preferred over efavirenz-based regimens in most adult populations, leading to gradual but measurable formulary shifts, particularly in middle-income countries. This substitution pressure is the primary long-term headwind for the Efavirenz Market.

Constraint 2: CNS Side Effect Profile Efavirenz is associated with central nervous system (CNS) side effects in approximately 10–15% of patients, including neuropsychiatric events. This adverse effect profile accelerates clinician preference for DTG in settings where both are available at comparable cost, limiting efavirenz's addressable patient population over time. The Infectious Disease Therapeutics Market is gradually realigning around newer agents with superior tolerability.

Competitive Ecosystem of the Efavirenz Market

The Efavirenz Market is characterized by a fragmented but price-competitive generic pharmaceutical landscape, with a small number of vertically integrated manufacturers dominating global procurement channels. The following profiles capture the key participants and their strategic positioning:

Teva: A global generic pharmaceutical leader, Teva maintains efavirenz product registrations across multiple key markets and leverages its broad distribution network to supply both institutional and retail channels. Its scale in the Generic Pharmaceuticals Market enables competitive pricing in tender-based procurement environments.
Macleods Pharmaceuticals: Macleods is a significant supplier of WHO-prequalified efavirenz FDC formulations, with a focused strategy on HIV, TB, and malaria products targeted at donor-funded markets. The company has expanded its manufacturing footprint in India to meet increasing demand from African procurement agencies.
Bristol-Myers Squibb: As the originator of efavirenz (marketed as Sustiva/Stocrin), Bristol-Myers Squibb played a foundational role in the molecule's clinical development and regulatory approval. While its direct commercial role has diminished following patent expiry and generic competition, it retains licensing agreements and brand recognition in select markets.
Strides Pharma: Strides operates with a strategic emphasis on regulated market exports and has obtained multiple regulatory approvals for its efavirenz-containing products. The company's focus on specialty generics and FDC formulations positions it within both the Pharmaceutical Formulation Market and global health supply chains.
Aurobindo Pharma: Aurobindo is one of the largest API and finished dose manufacturers of efavirenz globally, benefiting from backward integration into active pharmaceutical ingredient production. Its WHO-prequalified products participate extensively in PEPFAR and Global Fund supply programs.
Mylan: Mylan (now Viatris) was instrumental in making efavirenz-based FDCs accessible in low-income countries through aggressive generic entry and public health licensing agreements. The company's legacy supply relationships with global procurement agencies remain active under the Viatris umbrella.
Gilead Sciences: While Gilead's primary HIV portfolio is anchored in tenofovir alafenamide and integrase inhibitor-based combinations, it has historically participated in efavirenz FDC supply chains as a co-formulation partner. Gilead's market influence increasingly lies in shaping the therapeutic landscape that efavirenz competes within.
Cipla: Cipla is historically one of the most impactful players in making efavirenz accessible in developing markets. Its early entry into triple-combination efavirenz generics was a defining moment in HIV treatment affordability globally, and it continues to be a leading supplier in sub-Saharan Africa.
Hetero: Hetero is a vertically integrated manufacturer with significant capacity in efavirenz API and finished dose production. The company has secured WHO prequalification for multiple efavirenz-containing formulations and supplies to both government and institutional buyers across Africa and Asia.

Recent Developments & Milestones in the Efavirenz Market

January 2023: The WHO updated its consolidated HIV treatment guidelines to reinforce dolutegravir-based regimens as the preferred first-line option globally, creating renewed urgency among efavirenz manufacturers to defend volume share through price competitiveness and pediatric formulation investment.
March 2023: Aurobindo Pharma received an additional WHO prequalification for a reformulated efavirenz 600mg tablet with improved dissolution characteristics, reinforcing its position in global health procurement.
June 2023: The Global Fund announced updated price reference benchmarks for efavirenz-based FDCs in its tender framework for the 2024–2026 cycle, reflecting continued downward price pressure on the three-drug combination segment.
September 2023: Macleods Pharmaceuticals entered into a supply agreement with a major African national health authority for multi-year procurement of efavirenz/lamivudine/tenofovir FDC, securing forward revenue visibility through 2026.
November 2023: Regulatory submissions were filed by two Indian generic manufacturers for pediatric dispersible efavirenz tablet formulations with the USFDA under the PEPFAR Tentative Approval pathway, targeting the underserved children treatment segment.
February 2024: PEPFAR released updated formulary guidance acknowledging continued procurement of efavirenz-based regimens for specific population segments, including pregnant women in settings where dolutegravir access remains constrained.
July 2024: Cipla announced capacity expansion at its Goa manufacturing facility to accommodate increased production of antiretroviral FDCs including efavirenz combinations, in response to sustained demand from Sub-Saharan African markets.

Regional Market Breakdown for the Efavirenz Market

The global Efavirenz Market exhibits pronounced regional heterogeneity, driven by differential HIV prevalence rates, healthcare infrastructure, funding architecture, and formulary transition timelines.

Sub-Saharan Africa (within Middle East & Africa region) represents the largest geographic demand center, accounting for an estimated 45–50% of global efavirenz consumption by volume. Countries including South Africa, Nigeria, Uganda, and Kenya operate large national ART programs that continue to dispense efavirenz-based regimens to millions of patients. The region's CAGR is projected at approximately 3.5–4.2% through 2033, reflecting stable volume growth partially offset by gradual DTG formulary transition in middle-income African nations. The primary demand driver is the sheer scale of HIV-positive populations in active treatment.

Asia Pacific, particularly India and the ASEAN bloc, constitutes the second largest and potentially the fastest-growing regional segment, with an estimated CAGR of 5.5–6.0% through 2033. India's national ART program covers over 1.5 million patients, with efavirenz-based regimens remaining standard in many state-level programs. The Pharmaceutical Contract Manufacturing Market is also concentrated in India, where API producers serve both domestic and export demand.

North America represents the most mature regional market, characterized by declining efavirenz utilization as INSTI-based regimens have become standard of care. The United States market shows a negative to flat growth trajectory for efavirenz-specific products, with demand confined to patients with established tolerability on existing regimens or specific contraindications to newer agents.

Europe mirrors North America in terms of clinical migration away from efavirenz, with the United Kingdom, Germany, and France having largely transitioned formularies toward dolutegravir and bictegravir. Regional CAGR for Europe is estimated at 1.0–1.5%, driven primarily by residual patient continuity.

South America, particularly Brazil, Argentina, and surrounding markets, presents a mixed picture. Brazil's large national AIDS program has begun a phased transition to dolutegravir, but efavirenz procurement volumes remain significant through 2025–2026 as the transition completes. Regional CAGR is estimated at 3.0–3.8%, supported by government procurement commitments.

Supply Chain & Raw Material Dynamics for the Efavirenz Market

The supply chain architecture of the Efavirenz Market is deeply concentrated in South and East Asia, with India and China serving as the primary sources of active pharmaceutical ingredient (API) manufacturing capacity. This geographic concentration creates both efficiency advantages and systemic vulnerability to supply disruption.

Efavirenz API synthesis involves several key chemical precursors, including cyclopropylamine, trifluoromethyl acetylene derivatives, and specific chiral reagents. Price trends for these upstream intermediates have been directionally upward since 2021, driven by energy cost escalation in China, environmental compliance expenditures at chemical manufacturing facilities, and logistics cost inflation. The Active Pharmaceutical Ingredients Market has experienced structural cost increases that have exerted margin pressure on finished dose manufacturers.

The Active Pharmaceutical Ingredients Market dynamics in India are particularly

Efavirenz Market Segmentation

1. Type
- 1.1. Single Efavirenz
- 1.2. Two-drug combination
- 1.3. Three-drug combination
2. Application
- 2.1. Adults
- 2.2. Children
3. End User
- 3.1. Hospitals
- 3.2. Clinics
- 3.3. Others

Efavirenz Market Segmentation By Geography

1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
2. South America
- 2.1. Brazil
- 2.2. Argentina
- 2.3. Rest of South America
3. Europe
- 3.1. United Kingdom
- 3.2. Germany
- 3.3. France
- 3.4. Italy
- 3.5. Spain
- 3.6. Russia
- 3.7. Benelux
- 3.8. Nordics
- 3.9. Rest of Europe
4. Middle East & Africa
- 4.1. Turkey
- 4.2. Israel
- 4.3. GCC
- 4.4. North Africa
- 4.5. South Africa
- 4.6. Rest of Middle East & Africa
5. Asia Pacific
- 5.1. China
- 5.2. India
- 5.3. Japan
- 5.4. South Korea
- 5.5. ASEAN
- 5.6. Oceania
- 5.7. Rest of Asia Pacific

Efavirenz Market Regional Market Share

Higher Coverage

Lower Coverage

No Coverage

Efavirenz Market REPORT HIGHLIGHTS

Aspects	Details
Study Period	2020-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2020-2025
Growth Rate	CAGR of 4.78% from 2020-2034
Segmentation	By Type Single Efavirenz Two-drug combination Three-drug combination By Application Adults Children By End User Hospitals Clinics Others By Geography North America United States Canada Mexico South America Brazil Argentina Rest of South America Europe United Kingdom Germany France Italy Spain Russia Benelux Nordics Rest of Europe Middle East & Africa Turkey Israel GCC North Africa South Africa Rest of Middle East & Africa Asia Pacific China India Japan South Korea ASEAN Oceania Rest of Asia Pacific

1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Objective
- 1.4. Definitions and Assumptions
2. Executive Summary
- 2.1. Market Snapshot
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Challenges
- 3.3. Market Trends
- 3.4. Market Opportunity
4. Market Factor Analysis
- 4.1. Porters Five Forces
  - 4.1.1. Bargaining Power of Suppliers
  - 4.1.2. Bargaining Power of Buyers
  - 4.1.3. Threat of New Entrants
  - 4.1.4. Threat of Substitutes
  - 4.1.5. Competitive Rivalry
- 4.2. PESTEL analysis
- 4.3. BCG Analysis
  - 4.3.1. Stars (High Growth, High Market Share)
  - 4.3.2. Cash Cows (Low Growth, High Market Share)
  - 4.3.3. Question Mark (High Growth, Low Market Share)
  - 4.3.4. Dogs (Low Growth, Low Market Share)
- 4.4. Ansoff Matrix Analysis
- 4.5. Supply Chain Analysis
- 4.6. Regulatory Landscape
- 4.7. Current Market Potential and Opportunity Assessment (TAM–SAM–SOM Framework)
- 4.8. MIQ Analyst Note
5. Market Analysis, Insights and Forecast, 2021-2033
- 5.1. Market Analysis, Insights and Forecast - by Type
  - 5.1.1. Single Efavirenz
  - 5.1.2. Two-drug combination
  - 5.1.3. Three-drug combination
- 5.2. Market Analysis, Insights and Forecast - by Application
  - 5.2.1. Adults
  - 5.2.2. Children
- 5.3. Market Analysis, Insights and Forecast - by End User
  - 5.3.1. Hospitals
  - 5.3.2. Clinics
  - 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast - by Region
  - 5.4.1. North America
  - 5.4.2. South America
  - 5.4.3. Europe
  - 5.4.4. Middle East & Africa
  - 5.4.5. Asia Pacific
6. North America Market Analysis, Insights and Forecast, 2021-2033
- 6.1. Market Analysis, Insights and Forecast - by Type
  - 6.1.1. Single Efavirenz
  - 6.1.2. Two-drug combination
  - 6.1.3. Three-drug combination
- 6.2. Market Analysis, Insights and Forecast - by Application
  - 6.2.1. Adults
  - 6.2.2. Children
- 6.3. Market Analysis, Insights and Forecast - by End User
  - 6.3.1. Hospitals
  - 6.3.2. Clinics
  - 6.3.3. Others
7. South America Market Analysis, Insights and Forecast, 2021-2033
- 7.1. Market Analysis, Insights and Forecast - by Type
  - 7.1.1. Single Efavirenz
  - 7.1.2. Two-drug combination
  - 7.1.3. Three-drug combination
- 7.2. Market Analysis, Insights and Forecast - by Application
  - 7.2.1. Adults
  - 7.2.2. Children
- 7.3. Market Analysis, Insights and Forecast - by End User
  - 7.3.1. Hospitals
  - 7.3.2. Clinics
  - 7.3.3. Others
8. Europe Market Analysis, Insights and Forecast, 2021-2033
- 8.1. Market Analysis, Insights and Forecast - by Type
  - 8.1.1. Single Efavirenz
  - 8.1.2. Two-drug combination
  - 8.1.3. Three-drug combination
- 8.2. Market Analysis, Insights and Forecast - by Application
  - 8.2.1. Adults
  - 8.2.2. Children
- 8.3. Market Analysis, Insights and Forecast - by End User
  - 8.3.1. Hospitals
  - 8.3.2. Clinics
  - 8.3.3. Others
9. Middle East & Africa Market Analysis, Insights and Forecast, 2021-2033
- 9.1. Market Analysis, Insights and Forecast - by Type
  - 9.1.1. Single Efavirenz
  - 9.1.2. Two-drug combination
  - 9.1.3. Three-drug combination
- 9.2. Market Analysis, Insights and Forecast - by Application
  - 9.2.1. Adults
  - 9.2.2. Children
- 9.3. Market Analysis, Insights and Forecast - by End User
  - 9.3.1. Hospitals
  - 9.3.2. Clinics
  - 9.3.3. Others
10. Asia Pacific Market Analysis, Insights and Forecast, 2021-2033
- 10.1. Market Analysis, Insights and Forecast - by Type
  - 10.1.1. Single Efavirenz
  - 10.1.2. Two-drug combination
  - 10.1.3. Three-drug combination
- 10.2. Market Analysis, Insights and Forecast - by Application
  - 10.2.1. Adults
  - 10.2.2. Children
- 10.3. Market Analysis, Insights and Forecast - by End User
  - 10.3.1. Hospitals
  - 10.3.2. Clinics
  - 10.3.3. Others
11. Competitive Analysis
- 11.1. Company Profiles
  - 11.1.1. Teva
    - 11.1.1.1. Company Overview
    - 11.1.1.2. Products
    - 11.1.1.3. Company Financials
    - 11.1.1.4. SWOT Analysis
  - 11.1.2. Macleods Pharmaceuticals
    - 11.1.2.1. Company Overview
    - 11.1.2.2. Products
    - 11.1.2.3. Company Financials
    - 11.1.2.4. SWOT Analysis
  - 11.1.3. Bristol-Myers Squibb
    - 11.1.3.1. Company Overview
    - 11.1.3.2. Products
    - 11.1.3.3. Company Financials
    - 11.1.3.4. SWOT Analysis
  - 11.1.4. Strides Pharma
    - 11.1.4.1. Company Overview
    - 11.1.4.2. Products
    - 11.1.4.3. Company Financials
    - 11.1.4.4. SWOT Analysis
  - 11.1.5. Aurobindo Pharma
    - 11.1.5.1. Company Overview
    - 11.1.5.2. Products
    - 11.1.5.3. Company Financials
    - 11.1.5.4. SWOT Analysis
  - 11.1.6. Mylan
    - 11.1.6.1. Company Overview
    - 11.1.6.2. Products
    - 11.1.6.3. Company Financials
    - 11.1.6.4. SWOT Analysis
  - 11.1.7. Gilead Sciences.
    - 11.1.7.1. Company Overview
    - 11.1.7.2. Products
    - 11.1.7.3. Company Financials
    - 11.1.7.4. SWOT Analysis
  - 11.1.8. Cipla
    - 11.1.8.1. Company Overview
    - 11.1.8.2. Products
    - 11.1.8.3. Company Financials
    - 11.1.8.4. SWOT Analysis
  - 11.1.9. Hetero
    - 11.1.9.1. Company Overview
    - 11.1.9.2. Products
    - 11.1.9.3. Company Financials
    - 11.1.9.4. SWOT Analysis
- 11.2. Market Entropy
  - 11.2.1. Company's Key Areas Served
  - 11.2.2. Recent Developments
- 11.3. Company Market Share Analysis, 2025
  - 11.3.1. Top 5 Companies Market Share Analysis
  - 11.3.2. Top 3 Companies Market Share Analysis
- 11.4. List of Potential Customers
12. Research Methodology

List of Figures

Figure 1: Revenue Breakdown (million, %) by Region 2025 & 2033
Figure 2: Revenue (million), by Type 2025 & 2033
Figure 3: Revenue Share (%), by Type 2025 & 2033
Figure 4: Revenue (million), by Application 2025 & 2033
Figure 5: Revenue Share (%), by Application 2025 & 2033
Figure 6: Revenue (million), by End User 2025 & 2033
Figure 7: Revenue Share (%), by End User 2025 & 2033
Figure 8: Revenue (million), by Country 2025 & 2033
Figure 9: Revenue Share (%), by Country 2025 & 2033
Figure 10: Revenue (million), by Type 2025 & 2033
Figure 11: Revenue Share (%), by Type 2025 & 2033
Figure 12: Revenue (million), by Application 2025 & 2033
Figure 13: Revenue Share (%), by Application 2025 & 2033
Figure 14: Revenue (million), by End User 2025 & 2033
Figure 15: Revenue Share (%), by End User 2025 & 2033
Figure 16: Revenue (million), by Country 2025 & 2033
Figure 17: Revenue Share (%), by Country 2025 & 2033
Figure 18: Revenue (million), by Type 2025 & 2033
Figure 19: Revenue Share (%), by Type 2025 & 2033
Figure 20: Revenue (million), by Application 2025 & 2033
Figure 21: Revenue Share (%), by Application 2025 & 2033
Figure 22: Revenue (million), by End User 2025 & 2033
Figure 23: Revenue Share (%), by End User 2025 & 2033
Figure 24: Revenue (million), by Country 2025 & 2033
Figure 25: Revenue Share (%), by Country 2025 & 2033
Figure 26: Revenue (million), by Type 2025 & 2033
Figure 27: Revenue Share (%), by Type 2025 & 2033
Figure 28: Revenue (million), by Application 2025 & 2033
Figure 29: Revenue Share (%), by Application 2025 & 2033
Figure 30: Revenue (million), by End User 2025 & 2033
Figure 31: Revenue Share (%), by End User 2025 & 2033
Figure 32: Revenue (million), by Country 2025 & 2033
Figure 33: Revenue Share (%), by Country 2025 & 2033
Figure 34: Revenue (million), by Type 2025 & 2033
Figure 35: Revenue Share (%), by Type 2025 & 2033
Figure 36: Revenue (million), by Application 2025 & 2033
Figure 37: Revenue Share (%), by Application 2025 & 2033
Figure 38: Revenue (million), by End User 2025 & 2033
Figure 39: Revenue Share (%), by End User 2025 & 2033
Figure 40: Revenue (million), by Country 2025 & 2033
Figure 41: Revenue Share (%), by Country 2025 & 2033

List of Tables

Table 1: Revenue million Forecast, by Type 2020 & 2033
Table 2: Revenue million Forecast, by Application 2020 & 2033
Table 3: Revenue million Forecast, by End User 2020 & 2033
Table 4: Revenue million Forecast, by Region 2020 & 2033
Table 5: Revenue million Forecast, by Type 2020 & 2033
Table 6: Revenue million Forecast, by Application 2020 & 2033
Table 7: Revenue million Forecast, by End User 2020 & 2033
Table 8: Revenue million Forecast, by Country 2020 & 2033
Table 9: Revenue (million) Forecast, by Application 2020 & 2033
Table 10: Revenue (million) Forecast, by Application 2020 & 2033
Table 11: Revenue (million) Forecast, by Application 2020 & 2033
Table 12: Revenue million Forecast, by Type 2020 & 2033
Table 13: Revenue million Forecast, by Application 2020 & 2033
Table 14: Revenue million Forecast, by End User 2020 & 2033
Table 15: Revenue million Forecast, by Country 2020 & 2033
Table 16: Revenue (million) Forecast, by Application 2020 & 2033
Table 17: Revenue (million) Forecast, by Application 2020 & 2033
Table 18: Revenue (million) Forecast, by Application 2020 & 2033
Table 19: Revenue million Forecast, by Type 2020 & 2033
Table 20: Revenue million Forecast, by Application 2020 & 2033
Table 21: Revenue million Forecast, by End User 2020 & 2033
Table 22: Revenue million Forecast, by Country 2020 & 2033
Table 23: Revenue (million) Forecast, by Application 2020 & 2033
Table 24: Revenue (million) Forecast, by Application 2020 & 2033
Table 25: Revenue (million) Forecast, by Application 2020 & 2033
Table 26: Revenue (million) Forecast, by Application 2020 & 2033
Table 27: Revenue (million) Forecast, by Application 2020 & 2033
Table 28: Revenue (million) Forecast, by Application 2020 & 2033
Table 29: Revenue (million) Forecast, by Application 2020 & 2033
Table 30: Revenue (million) Forecast, by Application 2020 & 2033
Table 31: Revenue (million) Forecast, by Application 2020 & 2033
Table 32: Revenue million Forecast, by Type 2020 & 2033
Table 33: Revenue million Forecast, by Application 2020 & 2033
Table 34: Revenue million Forecast, by End User 2020 & 2033
Table 35: Revenue million Forecast, by Country 2020 & 2033
Table 36: Revenue (million) Forecast, by Application 2020 & 2033
Table 37: Revenue (million) Forecast, by Application 2020 & 2033
Table 38: Revenue (million) Forecast, by Application 2020 & 2033
Table 39: Revenue (million) Forecast, by Application 2020 & 2033
Table 40: Revenue (million) Forecast, by Application 2020 & 2033
Table 41: Revenue (million) Forecast, by Application 2020 & 2033
Table 42: Revenue million Forecast, by Type 2020 & 2033
Table 43: Revenue million Forecast, by Application 2020 & 2033
Table 44: Revenue million Forecast, by End User 2020 & 2033
Table 45: Revenue million Forecast, by Country 2020 & 2033
Table 46: Revenue (million) Forecast, by Application 2020 & 2033
Table 47: Revenue (million) Forecast, by Application 2020 & 2033
Table 48: Revenue (million) Forecast, by Application 2020 & 2033
Table 49: Revenue (million) Forecast, by Application 2020 & 2033
Table 50: Revenue (million) Forecast, by Application 2020 & 2033
Table 51: Revenue (million) Forecast, by Application 2020 & 2033
Table 52: Revenue (million) Forecast, by Application 2020 & 2033

Methodology

Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.

Quality Assurance Framework

Comprehensive validation mechanisms ensuring market intelligence accuracy, reliability, and adherence to international standards.

Multi-source Verification

500+ data sources cross-validated

Expert Review

200+ industry specialists validation

Standards Compliance

NAICS, SIC, ISIC, TRBC standards

Real-Time Monitoring

Continuous market tracking updates

Frequently Asked Questions

1. What are the major growth drivers for the Efavirenz Market market?

Factors such as are projected to boost the Efavirenz Market market expansion.

2. Which companies are prominent players in the Efavirenz Market market?

Key companies in the market include Teva, Macleods Pharmaceuticals, Bristol-Myers Squibb, Strides Pharma, Aurobindo Pharma, Mylan, Gilead Sciences., Cipla, Hetero.

3. What are the main segments of the Efavirenz Market market?

The market segments include Type, Application, End User.

4. Can you provide details about the market size?

The market size is estimated to be USD 141.69 million as of 2022.

5. What are some drivers contributing to market growth?

N/A

6. What are the notable trends driving market growth?

N/A

7. Are there any restraints impacting market growth?

N/A

8. Can you provide examples of recent developments in the market?

9. What pricing options are available for accessing the report?

Pricing options include single-user, multi-user, and enterprise licenses priced at USD 3690, USD 5820, and USD 9870 respectively.

10. Is the market size provided in terms of value or volume?

The market size is provided in terms of value, measured in million and volume, measured in .

11. Are there any specific market keywords associated with the report?

Yes, the market keyword associated with the report is "Efavirenz Market," which aids in identifying and referencing the specific market segment covered.

12. How do I determine which pricing option suits my needs best?

The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.

13. Are there any additional resources or data provided in the Efavirenz Market report?

While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.

14. How can I stay updated on further developments or reports in the Efavirenz Market?

To stay informed about further developments, trends, and reports in the Efavirenz Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.

Choose License Type

Tailored for you

In-depth Analysis Tailored to Specified Regions or Segments
Company Profiles Customized to User Preferences
Comprehensive Insights Focused on Specific Segments or Regions
Customized Evaluation of Competitive Landscape to Meet Your Needs
Tailored Customization to Address Other Specific Requirements

As requested- presale engagement was good, your perseverance, support and prompt responses were noted. Your follow up with vm’s were much appreciated. Happy with the final report and post sales by your team.

I have received the report already. Thanks you for your help.it has been a pleasure working with you. Thank you again for a good quality report

The response was good, and I got what I was looking for as far as the report. Thank you for that.

About Market Lens IQ

Market Lens IQ is a global market intelligence and strategic consulting firm delivering advanced syndicated research reports, customized industry analysis, competitive intelligence, and data-driven advisory solutions to organizations across international markets. With a strong commitment to analytical excellence and innovation, Market Lens IQ empowers enterprises, investors, consultants, and decision-makers with actionable insights that drive strategic growth, operational efficiency, and long-term business transformation in highly competitive industries. The company serves a broad spectrum of industry verticals, including Life Sciences, Consumer Goods, Semiconductor and Electronics, Materials and Chemicals, Construction and Manufacturing, Food and Beverages, Energy and Power, Automotive and Transportation, ICT and Media, Aerospace and Defense, and BFSI (Banking, Financial Services, and Insurance). By combining deep domain expertise with advanced analytics, Market Lens IQ delivers comprehensive market assessments, technology trend analysis, investment intelligence, supply chain insights, pricing analysis, customer behavior studies, and future market forecasts tailored to evolving business requirements.

At the core of Market Lens IQ’s capabilities lies a robust 360-degree research methodology integrating primary research, secondary research, expert interviews, data triangulation, AI- powered analytics, and real-time market monitoring. Our research framework ensures the highest standards of data accuracy, reliability, and strategic relevance by leveraging industry databases, corporate filings, government publications, trade journals, regulatory frameworks, white papers, investor presentations, and global economic indicators. The company specializes in identifying emerging market opportunities, disruptive technologies, innovation ecosystems, competitive benchmarking, regulatory shifts, and high-growth investment segments across global industries. Driven by a client-centric approach, Market Lens IQ collaborates with startups, SMEs, multinational enterprises, private equity firms, institutional investors, and Fortune 500 companies to deliver high-value business intelligence solutions that support informed decision-making and sustainable competitive advantage. Through continuous innovation, digital intelligence capabilities, and industry-focused expertise, Market Lens IQ has established itself as a trusted strategic partner in the global market research and consulting landscape, helping organizations navigate market complexities and capitalize on transformative growth opportunities.

Key Insights into the Efavirenz Market

Dominance of Three-Drug Combination Segment in the Efavirenz Market

Key Market Drivers and Constraints in the Efavirenz Market

Several quantifiable forces shape the demand and supply trajectory of the Efavirenz Market. Understanding these dynamics requires a data-centric examination of both accelerators and headwinds.

Competitive Ecosystem of the Efavirenz Market

Teva: A global generic pharmaceutical leader, Teva maintains efavirenz product registrations across multiple key markets and leverages its broad distribution network to supply both institutional and retail channels. Its scale in the Generic Pharmaceuticals Market enables competitive pricing in tender-based procurement environments.
Macleods Pharmaceuticals: Macleods is a significant supplier of WHO-prequalified efavirenz FDC formulations, with a focused strategy on HIV, TB, and malaria products targeted at donor-funded markets. The company has expanded its manufacturing footprint in India to meet increasing demand from African procurement agencies.
Bristol-Myers Squibb: As the originator of efavirenz (marketed as Sustiva/Stocrin), Bristol-Myers Squibb played a foundational role in the molecule's clinical development and regulatory approval. While its direct commercial role has diminished following patent expiry and generic competition, it retains licensing agreements and brand recognition in select markets.
Strides Pharma: Strides operates with a strategic emphasis on regulated market exports and has obtained multiple regulatory approvals for its efavirenz-containing products. The company's focus on specialty generics and FDC formulations positions it within both the Pharmaceutical Formulation Market and global health supply chains.
Aurobindo Pharma: Aurobindo is one of the largest API and finished dose manufacturers of efavirenz globally, benefiting from backward integration into active pharmaceutical ingredient production. Its WHO-prequalified products participate extensively in PEPFAR and Global Fund supply programs.
Mylan: Mylan (now Viatris) was instrumental in making efavirenz-based FDCs accessible in low-income countries through aggressive generic entry and public health licensing agreements. The company's legacy supply relationships with global procurement agencies remain active under the Viatris umbrella.
Gilead Sciences: While Gilead's primary HIV portfolio is anchored in tenofovir alafenamide and integrase inhibitor-based combinations, it has historically participated in efavirenz FDC supply chains as a co-formulation partner. Gilead's market influence increasingly lies in shaping the therapeutic landscape that efavirenz competes within.
Cipla: Cipla is historically one of the most impactful players in making efavirenz accessible in developing markets. Its early entry into triple-combination efavirenz generics was a defining moment in HIV treatment affordability globally, and it continues to be a leading supplier in sub-Saharan Africa.
Hetero: Hetero is a vertically integrated manufacturer with significant capacity in efavirenz API and finished dose production. The company has secured WHO prequalification for multiple efavirenz-containing formulations and supplies to both government and institutional buyers across Africa and Asia.

Recent Developments & Milestones in the Efavirenz Market

January 2023: The WHO updated its consolidated HIV treatment guidelines to reinforce dolutegravir-based regimens as the preferred first-line option globally, creating renewed urgency among efavirenz manufacturers to defend volume share through price competitiveness and pediatric formulation investment.
March 2023: Aurobindo Pharma received an additional WHO prequalification for a reformulated efavirenz 600mg tablet with improved dissolution characteristics, reinforcing its position in global health procurement.
June 2023: The Global Fund announced updated price reference benchmarks for efavirenz-based FDCs in its tender framework for the 2024–2026 cycle, reflecting continued downward price pressure on the three-drug combination segment.
September 2023: Macleods Pharmaceuticals entered into a supply agreement with a major African national health authority for multi-year procurement of efavirenz/lamivudine/tenofovir FDC, securing forward revenue visibility through 2026.
November 2023: Regulatory submissions were filed by two Indian generic manufacturers for pediatric dispersible efavirenz tablet formulations with the USFDA under the PEPFAR Tentative Approval pathway, targeting the underserved children treatment segment.
February 2024: PEPFAR released updated formulary guidance acknowledging continued procurement of efavirenz-based regimens for specific population segments, including pregnant women in settings where dolutegravir access remains constrained.
July 2024: Cipla announced capacity expansion at its Goa manufacturing facility to accommodate increased production of antiretroviral FDCs including efavirenz combinations, in response to sustained demand from Sub-Saharan African markets.

Regional Market Breakdown for the Efavirenz Market

Supply Chain & Raw Material Dynamics for the Efavirenz Market

The Active Pharmaceutical Ingredients Market dynamics in India are particularly

Efavirenz Market Segmentation

1. Type
- 1.1. Single Efavirenz
- 1.2. Two-drug combination
- 1.3. Three-drug combination
2. Application
- 2.1. Adults
- 2.2. Children
3. End User
- 3.1. Hospitals
- 3.2. Clinics
- 3.3. Others

Efavirenz Market Segmentation By Geography

1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
2. South America
- 2.1. Brazil
- 2.2. Argentina
- 2.3. Rest of South America
3. Europe
- 3.1. United Kingdom
- 3.2. Germany
- 3.3. France
- 3.4. Italy
- 3.5. Spain
- 3.6. Russia
- 3.7. Benelux
- 3.8. Nordics
- 3.9. Rest of Europe
4. Middle East & Africa
- 4.1. Turkey
- 4.2. Israel
- 4.3. GCC
- 4.4. North Africa
- 4.5. South Africa
- 4.6. Rest of Middle East & Africa
5. Asia Pacific
- 5.1. China
- 5.2. India
- 5.3. Japan
- 5.4. South Korea
- 5.5. ASEAN
- 5.6. Oceania
- 5.7. Rest of Asia Pacific

Efavirenz Market Regional Market Share

Higher Coverage

Lower Coverage

No Coverage

Tailored for you